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Alterations in the production of vasodilator or vasoconstrictor substances or alteration in the rate of their degradation or diffusion may change the vascular tone. 1 Vasodilator substances such as prostacyclin, natriuretic peptide, hyperpolarizing factor and especially nitric oxide have an important role. Reduced production or bioavailability of nitric oxide may cause vasoconstriction, increased platelet aggregation, thrombus formation, increased smooth muscle proliferation and leukocyte adhesion.
1,2
Endothelin-1 is the most important peptide produced in the endothelium. It causes vasoconstriction and smooth muscle proliferation with remodelling and impairment of endothelial function. Endothelial dysfunction was not observed in patients with hypertension without a family history of cardiovascular disease and without other risk factors of atherosclerosis. 3 However, deterioration of endothelial function was found in patients with hypertension with risk factors of atherosclerosis and was most pronounced in those with coronary artery disease. 3 Numerous systems and factors contribute to the development of hypertension, including the sympathetic nervous system, the renin-angiotensin-aldosterone system, extracellular matrix and endothelin. Interaction between numerous environmental factors regulating blood pressure including sodium intake and use of tobacco, alcohol, caffeine, nonsteroidal anti-inflammatory drugs, sympathomiometic amines, glucocorticoids and other drugs and genetic traits are necessary for the development of hypertension. In addition to cigarette smoking, hypertension, dyslipidaemia, diabetes mellitus and physical inactivity, a family history of coronary artery disease is an important risk factor for coronary artery disease. Polymorphisms within the genes of the renin-angiotensin-aldosterone system, sympathetic nervous system, endothelin-1 and nitric oxide synthase but not within paraoxonases may contribute to the development and progression of cardiovascular disease. 4, 5 Polymorphisms within the endothelial nitric oxide synthase gene were not associated with an increased risk of myocardial infarction. 6 Animal models of hypertension, especially in the rat, have found quantitative trait loci harbouring one or several hypertension-related genes. 7 However, translation of these findings into humans with hypertension remains challenging. 7 In previous studies, vascular endothelial cells have been shown to functionally express a local autocrine/paracrine regulatory pathway driven by endogenously expressed, chemically authentic morphine, its cognate opiate alkaloid-selective mu3 and mu4 receptors and constitutive nitric oxide. 8, 9 The authors have also reported that morphine-mediated activation of nitric oxide/cyclic guanosine monophosphate signalling pathways results in significant vasodilatation, which suggests that opiate receptors might be important potential therapeutic targets for restoring normotensive vascular tone in patients with hypertension. [8] [9] [10] The presence of chemically authentic morphine has been shown in vascular endothelial cells obtained from the human atria, human white blood cells, human plasma and several human cancer cell lines. 8, 9, 11, 12 A functionally competent mu3/mu4 receptor/nitric oxide-coupled regulatory pathway was also characterized in human multilineage progenitor cells. 13 Morphine has also been shown to significantly reduce mean arterial pressure and heart rate in spontaneously hypertensive rats.
14 Endogenous morphine derived from defined cellular sources and circulating in the plasma seems to have an important role in promoting coordinated, on demand, vasomotor responsiveness, to diverse physiological stimuli.
In this issue of the Journal of Human Hypertension, Banach et al. 15 have sought to examine morphinemediated changes in the expression of genes associated with hypertension using two independent cell models: preparations of human white blood cells and human multilineage progenitor cells. On the basis of the obtained results, they observed that morphine treatment of white blood cells and stem cells altered the profile expression of 16 candidate genes in hypertension. Most of the genes associated with blood pressure regulation in this study were downregulated. Only two genes were observed to be significantly upregulated after treatment with morphine: adrenergic, b, receptor kinase 2 in stem cells and adrenergic, b-3, receptor in white blood cells.
The morphine-mediated decreases in the expression of a1B-adrenergic receptor in stem cells and in the decreased expression of b-adrenergic receptor kinase 1 in white blood cells are consistent with an antihypertensive role. The morphine-mediated 10-fold decrease in endothelin-3 expression, the altered expression by morphine of hypertension-associated candidate genes in the kidney and in the adrenal gland, as well as the altered expression of hypertension-associated genes involved in proinflammation all suggest an antihypertensive role for morphine.
These results imply that endogenous morphine possesses antihypertensive properties. However, the authors correctly state that the limitation of their study is mainly connected to the fact that the functional consequences of morphine-mediated effects have not been tested. Their data need to be confirmed, and such confirmation would have important clinical implications.
